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Abstract: The development of suspect or non-target screening methods to detect xenobiotics in
biological fluids is essential to properly understand the exposome and assess its adverse health
effects on humans. In order to fulfil that aim, the biomonitorization of human fluids is compulsory.
However, these methods are not yet extensively developed, especially for polar organic xenobiotics
in biofluids such as milk, as most works are only focused on certain analytes of interest. In this
work, a multi-target analysis method to determine 245 diverse xenobiotics in milk by means of Ultra
High Performance Liquid Chromatography (UHPLC)-qOrbitrap was developed. Under optimal
conditions, liquid milk samples were extracted with acetonitrile in the presence of anhydrous Na2SO4
and NaCl, and the extracts were cleaned-up by protein precipitation at low temperature and Captiva
Non-Drip (ND)—Lipids filters. The optimized method was validated at two concentration-levels
(10 ng/g and 40 ng/g) obtaining satisfactory figures of merit for more than 200 compounds. The
validated multi-target method was applied to several milk samples, including commercial and
breast milk, provided by 4 healthy volunteers. Moreover, the method was extended to perform
suspect analysis of more than 17,000 xenobiotics. All in all, several diverse xenobiotics were detected,
highlighting food additives (benzothiazole) or phytoestrogens (genistein and genistin) in commercial
milk samples, and stimulants (caffeine), plasticizers (phthalates), UV filters (benzophenone), or
pharmaceuticals (orlistat) in breast milk samples.
Keywords: xenobiotics; multi-target analysis; suspect screening; UHPLC-qOrbitrap; commercial
milk; breast milk
1. Introduction
Unexpected increases of health-related issues in humans at different life stages have
raised concern about exposure to chemical compounds, since around 300 million tons of
synthetic compounds are used in industrial and consumer products annually [1]. Moreover,
the list of compounds with emerging interest is rapidly growing due to the metabolites
and/or transformation products of the chemicals, alongside the newly synthetized ones [1].
Therefore, all living organisms are exposed to an overwhelming number of chemical
compounds that can potentially trigger adverse health effects [2]. This way, the concept
of “exposome”, which engages all non-genetic factors that can be linked to adverse health
outcomes [3,4], has gained considerable recognition [5].
At present, it is well stablished that around three quarters of human diseases are
related to the exposure to chemical compounds [6]. Monitorization of the exposome could
turn out as an useful tool to evaluate potential health risk and open new frontiers in the
comprehension of external, internal and non-specific exposures and their consequences
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on the health of living organisms, especially of humans [7]. Monitorization of biological
fluids and tissues to find relevant biomarkers from the epidemiological point of view could
identify potential subpopulations to suffer adverse health effects [8,9]. In this context,
biomonitorization is gaining importance in epidemiological studies [10] and the European
Union is boosting the biomonitorization of chemical compounds in humans to inform the
understanding of exposure-response relationship [11].
Concerning biological fluids, urine and blood are typically selected [12]. However,
bioaccumulation of organic molecules in breast milk has also drawn special attention in
the last decade, since it is the mayor exposure source of contaminants to breastfed new-
borns [12] and a well-established risk factor for breast cancer in women [13]. Moreover, the
increasing demand for human breast milk has caused a rapid growth of milk banks that do
not follow regulations regarding organic micropollutants due to the absence of appropriate
analytical tools, focusing only on the elimination of microorganisms [14,15]. Since breast
is mainly build up with adipose tissue and the lipid content of the milk can go up to
5%, very persistent lipid-soluble compounds are likely to accumulate in breast milk [16].
Anyhow, due to the considerable water content of milk, more polar and water-ionizable
compounds can also be present there [16]. Besides human breast milk, animal origin milk
has also been the centre of attention in the last decade, especially bovine milk. Milk is
a major constituent of the human diet worldwide and the widespread use of drugs and
pesticides in dairy farming and agricultural practises, usually contaminate it with their
residues [17]. Moreover, the increasing usage of illegal or off-license drugs and pesticides
in dairy production further increases health risk to consumers [18].
Considering the undefinable amount of organic xenobiotics that can be present in milk
and could have potential adverse health effects, the development of non-target methods is
compulsory to properly identify all of them [19,20]. However, there is a lack of literature
covering a wide range of chemical compounds in milk as far as polarity and hydrophilicity
is concerned. In fact, most of the analysis have been limited to the classical non-polar
priority compounds [21–25]. The determination of more polar compounds in a complicated
matrix like milk, with variable quantities of lipids, proteins, sugars, vitamins or minerals,
remains as a challenging task [25,26]. In recent literature, most works focus specifically on
selected target compounds [27], such as selected pharmaceuticals [17,28], antibiotics [29–31],
or phthalates [26], instead of analysing the multiple xenobiotics present [23].
In the analytical procedures to determine xenobiotics in milk, liquid-liquid extraction
(LLE) using non-polar solvents (e.g., diethyl ether, hexane or dichloromethane) is one
the most used extraction technique [32,33]. By adding ethanol to the non-polar solvents
or using more polar solvents such as acetonitrile (AcN) or methanol (MeOH), extraction
of the more polar xenobiotics is favoured [24]. Moreover, the addition of salts such as
anhydrous magnesium sulphate (MgSO4) or sodium chloride (NaCl) enhances phase
separation and ensures higher recoveries by salting-out effect. According to the literature,
the effectiveness of LLE is improved by vigorously handshaking or using vortex [17,25].
Following the mentioned approaches, some works have employed high speed solvent
extraction procedures, which also use solvent mixtures to get medium polarities (e.g.,
acetone/hexane mixtures) and salts (e.g., anhydrous sodium sulphate (Na2SO4)) to extract
non-polar and slightly polar compounds [34,35].
Under those non-selective extraction conditions, a significant amount of proteins
and lipids is co-extracted alongside the organic xenobiotics [32,33]. Although a protein
precipitation step is often performed just after the extraction step [25,33,36], a further
clean-up of the extracts is mandatory to minimize the matrix-effect at the detection step. In
this sense, solid phase extraction (SPE) has been mainly investigated for the removal of
interferences. Considering the wide polarity of analytes, polymeric based sorbents such as
Oasis hydrophilic-lipophilic balance (HLB) have been widely used [29,30,37]. Clean-up
mechanisms based on size exclusion such as miniaturized gel permeation chromatogra-
phy [38] or Captiva ND-Lipids filters [25] are adequate for removing big biomolecules
as well.
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In the determination of polar organic compounds, liquid-chromatography (LC) is
mostly used since it allows the separation of a broad spectrum of compounds as far as
polarity is concerned, which can be interesting in the analysis of emerging compounds and
their metabolites and/or transformation products [39,40]. As for the detection step, mass
spectrometry (MS) is the selected option in the most of recent works since it solves coelution
problems that other detectors have [32,41]. Electrospray ionization (ESI) is preferably used
to couple the MS to LC since it is capable of analysing ionizable compounds within a large
molecular weight range [42]. High resolution mass spectrometry (HRMS) has shown to
be a very powerful tool to identify unknown compounds present in milk and to get a
more holistic understating of the exposome [23,25]. Hybrid detectors such as quadrupole-
Time of Flight (qTOF) or quadrupole-Orbitrap (qOrbitrap) allow performing tandem mass
spectrometry at high resolution obtaining both the MS1 (pseudomolecular ion and isotopic
profile) and MS2 (fragmentation spectra) at high resolution, which allows the elucidation
of unknown compounds [43].
According to the literature, the full scan data-dependent (dd)—MS2 acquisition mode
has been used in a wide variety of samples without previous selection of suspects (dis-
covery mode), in particular, in the analysis of river water [44], fish muscle [45], packaging
materials [46], or sediments [47]. The main advantage of this acquisition mode is that the
fragments in MS2 can be directly linked to their respective precursor in MS1 being the
identification easier. On the downside, not all precursors are fragmented but only the
selected (confirmation) or the most intense ones (discovery), as mentioned above [10,27].
Taking all into consideration, the analytical challenge nowadays is to develop methods
to simultaneously detect the major number of polar xenobiotics present in human milk.
The objective of the present work was to optimize the extraction and clean-up of a multi-
target method (245 diverse analytes) for the determination of emerging xenobiotics in milk
samples, and then, to extend the method to suspect screening with the aim of increasing
the number of compounds (approx. 17,800 compounds) monitored in the samples, thereby
gaining a better understanding of the exposome.
2. Materials and Methods
2.1. Reagents
The 245 target analytes were selected to mimic as realistically as possible real exposure
to xenobiotics that living organisms suffer throughout their entire lifespan, including di-
verse analytes in terms of polarity, acidity/basicity, functional groups, structures, molecular
weight and usage. The selected compounds are listed in Supplementary Table S1 together
with the commercial vendors, purity of the standards and the solvents used for preparing
the stock solution of each individual compound. Standard stock solutions were prepared in
the 100–10,000 µg/g range using MeOH (99.9%, UHPLC-MS quality, Scharlab, Barcelona,
Spain), AcN (ChromAR HPLC, Macron Fine Chemicals, Avantor, Radnor Township, PA,
USA), acetone (ChromAR HPLC), EtOH (ChromAR HPLC), dimethyl sulfoxide (DMSO,
Applichem, Panreac, Barcelona, Spain) and/or Milli-Q water (H2O, < 0.05 µS/cm, Millipore
185, Millipore, Burlington, MA, USA), depending on the target compound. Solutions up
to 2 µg/g containing all the target compounds (214 in optimization and 245 at validation)
were prepared in MeOH and kept at −20 ◦C in the darkness. A surrogate mixture solution
of 1 µg/g containing [2H5]-atrazine, [13C3]-caffeine, [2H8]-ciprofloxacin, [2H6]-diuron and
[2H5]-enrofloxacin was separately prepared in MeOH and stored under the same condi-
tions as the target analytes. All solutions were freshly prepared according to the specific
experimentation requirements.
AcN, MeOH, Milli-Q water, acetic acid (HOAc, 100%, Merck, Darmstadt, Germany),
trifluoroacetic acid (TFA, >99.5%, Sigma-Aldrich, Darmstandt, Germany) and trichloroacetic
acid (TCA, >99.5%, Sigma-Aldrich), formic acid (HCOOH, ≥98.0, Honeywell, Fluka,
Muskegon, MI, USA), anhydrous MgSO4 (99.5%, Alfa Aesar, Haverhill, MA, USA), an-
hydrous Na2SO4 (100%, Panreac, Barcelona, Spain), and NaCl (100%, Merck, Darmstadt,
Germany) were used during extraction and/or clean-up procedures. Ethylenediaminete-
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traacetic acid (EDTA, ≥99%, Panreac, Barcelona, Spain), NaOH pellets (≥99%, Merck,
Darmstadt, Germany) and hydrochloric acid (HCl, 36%, Merck, Darmstadt, Germany)
were used for preparing 30 mM EDTA (pH 4.0), 1 M NaOH (pH 13.0) and 0.1 mM HCl
(pH 4.0) solutions, respectively. Ammonium chloride (NH4Cl, 25%, Panreac, Barcelona,
Spain) and ammonia (NH3, 25%, AppliChem, Panreac, Barcelona, Spain) were also used
for preparing 0.5 M ammonia buffer (NH4+/NH3, pH 9.0). For the clean-up procedures,
Captiva Non-Drip (ND)-Lipid (100 mg, 3 mL, Agilent Technologies, Santa Clara, CA, USA)
filters and Oasis HLB SPE cartridges (200 mg, 6 mL, Waters, Milford, MA, USA) were tested.
Nitrogen (N2, 99.999%, Air Liquide, Paris, France) was used for evaporating the extracts.
Finally, HCOOH, Milli-Q water and AcN (UHPLC-MS grade) used as mobile phase in the
UHPLC-qOrbitrap were provided by Fischer Scientific (Merelbeke, Belgium). Nitrogen
gas (99.999%), provided by Air Liquide (Madrid, Spain), was used as both nebulizer and
drying gas.
2.2. Milk Samples
Several commercial and human breast milk samples were used in order to optimize
the method and detect possible xenobiotics. For method optimization, treated (pasteurized)
whole bovine (Bos taurus) milk was used. For method application, freeze-dried milk powder
and untreated raw bovine milk were also employed. All commercial milk samples were
purchased from a local market. As for the breast milk samples, they were provided by
four healthy and primiparous mothers from Biscay and anonymized for ethical reasons
according to the the Bioethics Committee rules of the University of the Basque Country
(CEISH-UPV/EHU, BOPV 32, 17/2/2014, M10_2020_230). All milk samples were stored at
−20 ◦C until the analysis.
2.3. Extraction of Xenobiotics
Prior to extraction, all milk samples were thawed at room temperature. The op-
timization of the extraction step was carried out by spiking bovine milk samples with
214 target analytes to get concentrations around 300 ng/g in the final extract. Extractions
were performed using vortex at maximum speed for 1 min, and the extraction solvents
tested were: (i) AcN, (ii) AcN with different combinations of MgSO4, Na2SO4, and NaCl,
(iii) AcN:Milli-Q water (95:5, v/v) with 0.1% EDTA, (iv) MeOH:HOAc (95:5, v/v) and
(v) MeOH with TFA or TCA (80:20, v/v).
Under optimal conditions, 1 mL of whole liquid milk and 3 mL of AcN were placed in
polypropylene falcon tubes (40 mL, Deltalab, Barcelona, Spain) and 0.5 g of Na2SO4 and
0.1 g of NaCl were added to the mixture while the extraction was accelerated using vortex
at maximum speed for 1 min.
2.4. Clean-Up
Once the extraction step was over, samples were centrifuged at low temperature
(4 ◦C) for 15 min at 10,000 rpm (Centrifuge Allegra X-30R, F2402H, Beckman Coulter,
Wycombe, UK) and the supernatant was quantitatively recovered. To enhance protein
precipitation, the collected fractions were kept in the freezer at −20 ◦C overnight. After
protein precipitation, the supernatant was quantitatively recovered on a glass lab tube for
a further clean-up step.
For the optimisation of the additional clean-up step, Captiva ND-Lipids filters and
Oasis HLB cartridges at different conditions were tested individually and combined. For
the optimal usage of the Captiva ND-Lipid filters, the recommendations of the supplier
were followed [48]. The supernatant recovered after protein precipitation was evaporated
to ~500 µL under a gentle stream of N2 in a Turbovap LV Evaporator (Zymark, Biotage,
Uppsala, Sweden) at 35 ◦C. Then, 1500 µL of AcN acidified with 0.1% of HCOOH was
added to the cartridge as crash solvent followed by the ~500 µL of extract. The mixture was
homogenised with the help of a pipette and filtered through the cartridge for biomolecules
removal. Finally, the Captiva filters were dried under vacuum.
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When Oasis HLB cartridges were used either for clean-up purposes or for solvent
exchange after the addition of EDTA, the procedure explained hereinafter was carried out.
The extracts obtained either from Captiva ND-Lipid filters or protein precipitation were
evaporated to dryness at 35 ◦C under a N2 stream in the Turbovap and were reconstituted in
5 mL EDTA (30 mM, pH 4.0) prior to their loading onto the Oasis HLB cartridge. The pH of
the solution was adjusted in each experiment using 0.5 mL and 1.0 mL of 0.5 M NH4+/NH3
buffer to obtain pH 6.0 and 9.0, respectively. The extracts were loaded onto Oasis HLB
cartridges that were previously conditioned with 5 mL of MeOH and equilibrated with
5 mL of Milli-Q water adjusted at the corresponding pH (4.0, 6.0 or 9.0). After loading the
samples, 5 mL of Milli-Q water were used as washing solution and the cartridges were
completely dried under vacuum before the elution. The analytes were recovered using
5 mL of MeOH.
Under optimal conditions, the supernatant recovered from protein precipitation at
low temperature was evaporated to ~500 µL under a gentle stream of N2 at 35 ◦C and the
Captiva ND-Lipids protocol was followed.
2.5. UHPLC-qOrbitrap Analysis
The extracts obtained after clean-up were evaporated to dryness and re-dissolved in
200 µL MeOH. All samples and solutions were filtered before the analysis using 0.22 µm
polypropylene filters (Membrane Solutions) in chromatography vials and kept in the
freezer at −20 ◦C until analysis. A Dionex Ultimate 3000 UHPLC (Thermo Fisher Scientific,
Waltham, MA, USA) coupled to a high-performance Q Exactive Focus Orbitrap (q-Orbitrap,
Thermo Fisher Scientific, Waltham, MA, USA) mass analyzer with a heated electrospray
ionization source (HESI, Thermo Fisher Scientific, Waltham, MA, USA) was used for the
analysis of the xenobiotics. For instrumental control, Xcalibur 3.1 (Thermo Fischer Scientific,
Waltham, MA, USA) was used.
Analyte separation was performed in an ACE UltraCore XB-C18 (2.1 mm × 150 mm,
1.7 µm) column with a pre-filter (2.1 mm ID, 0.2 µm) from Phenomenex. Milli-Q water
(A line) and AcN (B line) were used as mobile phase, both containing 0.1% HCOOH and
5 mM ammonium acetate for positive and negative ionization modes, respectively. Column
flow was set at 0.3 mL/min and the temperature was maintained at 50 ◦C. Gradient elution
started with 13% B that changed to 50% B in 10 min. Then, the composition of the B line
was increased to 95% in 3 min and kept for 3 min. Finally, the mobile phase composition
was changed to the initial conditions in 3 min.
Regarding the HESI parameters, spray voltage was set at 3.2 kV for positive and 3.5 kV
for negative ionization modes. For positive ionization, the capillary temperature was set
at 320 ◦C, the sheath gas at 40 arbitrary units (au), the auxiliary gas at 15 au and 310 ◦C,
and the sweep gas at 1 au. For negative ionization, the capillary temperature was set at
300 ◦C, the sheath gas at 40 arbitrary units (au), the auxiliary gas at 15 au and 280 ◦C, and
the sweep gas at 1 au.
External calibration of the qOrbitrap mass analyzer was performed every three days
using Pierce LTQ ESI (Thermo Fisher Scientific, Waltham, MA, USA) calibration solutions.
Measurements were performed in negative and positive ionization modes in the Full
scan—data dependent MS2 (Full MS-ddMS2) discovery acquisition mode in the m/z
70–1050 Da range. After a complete scan at 70,000 FWHM resolution at m/z 200, three
scans were performed in the m/z 100–600 Da range at 17,500 FWHM at m/z 200 with an
isolation window of 3.0 m/z with a stepped collision energy (SCE) of 10, 45, and 90. The
ddMS2 scans were run with an automatic intensity threshold and dynamic exclusion. ACG
target was set at 5e4 and its minimum was set at 8.00e3.
2.6. Target Analysis and Suspect Screening
Target analysis and quantification was performed using the TraceFinder 5.0 software
(Thermo Fischer Scientific, Waltham, MA, USA), which contained a homemade database
including the retention time, exact mass (included in Supplementary Table S1), isotopic
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pattern and characteristic MS2 fragments of each target compound. Regarding the criteria
for target identification and subsequent quantification, a 60 s window was permitted for the
retention times, while a 5 ppm error was allowed for monoisotopic masses and fragment
ions. Moreover, 70% fitting was accepted for experimental and theoretical isotopic patterns.
Suspect screening was performed using the Compound Discoverer 3.1 program
(Thermo Fisher Scientific, Waltham, MA, USA), and as suspect list, compounds included in
the mzCloud library were used (approx. 17,800 compounds). From the detected xenobi-
otics, endogenous compounds were discarded using The Human Metabolome Database
(HMDB, https://hmdb.ca/). To identify suspects, first, only features with a Lorentzian
chromatographic peak shape and a minimum peak area of 107 were considered. More-
over, the feature should be present in the three replicates performed for each sample and
the group variance should be lower than 30%. The ratio with respect to the procedural
blanks should be equal or higher than 10 as well. The Compound Discoverer 3.1 program
provided all the features that, according to their exact mass and isotopic profile, matched
with one or several of the compounds in the suspect list. Then, fitting higher than 70%
in the case of the fragmentation spectrum was considered using the mzCloud library. Fi-
nally, retention time was considered before confirmation: (i) when the pure standard was
available, a deviation of ±0.1 min was admitted, and (ii) when not available, an estimation
of the theoretical retention time was performed using the retention time index platform
(http://rti.chem.uoa.gr/).
2.7. Method Validation
The analytical method was validated at two concentration levels after spiking bovine
whole milk samples with the target analytes at 10 ng/g and 40 ng/g. Apart from the
xenobiotics used in the optimization (214 compounds), 31 new compounds were added
in order to have an even wider variety of analytes and mimic more realistically real cases
(Supplementary Table S1). Extractions were performed in triplicate to calculate procedural
repeatability. Procedural blanks were also analysed in triplicate to check for possible cross-
contamination or contamination through the process. All samples were spiked at 25 ng/g
with a surrogate mixture containing [2H5]-atrazine, [13C3]-caffeine, [2H8]-ciprofloxacin,
[2H6]-diuron, and [2H5]-enrofloxacin for recovery correction.
For absolute recovery calculation, an external calibration consisting of 8 points was
built between the instrumental limit of quantification (LOQinst) and 300 ng/g. Calibration
points corresponding to 2, 5, 10, 25, and 50 ng/g were injected in triplicate for LOQinst
calculation. Instrumental repeatability was determined from the 50 ng/g calibration point
injected in triplicate as well. Instrumental limits of identification (LOIinst) were determined
from the external calibration.
The apparent recoveries were determined by two different strategies: (i) surrogate
correction and (ii) matrix-matched calibration. As for the surrogate correction, the absolute
recoveries were corrected with the recoveries of the corresponding surrogates. Regarding
the matrix-matched calibration, analyte-free commercial milk samples were spiked at
7 concentration-levels with 245 target compounds between the procedural limit of quan-
tification (LOQproc) and 60 ng/g in milk. Calibration points corresponding to 1, 2, 5, and
10 ng/g in milk were injected in triplicate for LOQproc calculation. Procedural limits of
identification (LOIproc) were calculated from the matrix-matched calibration as well. Both
external and matrix-matched calibrations were injected twice, at the beginning and the
end of the sequence, in order to examine possible signal drift. MeOH was injected every
6 injections along the sequence to check for possible carryover.
3. Results and Discussion
3.1. Protein Precipitation Optimization
Centrifugation at low temperature [36] and sample freezing in the presence of an
organic solvent [25] are reported to be effective for protein precipitation after performing
the extraction. These strategies can be combined with Captiva ND-Lipids filters for further
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clean-up to minimize matrix-effect [25,45]. Other alternative methods, such as the addition
of strong acids like TFA and TCA also promote protein precipitation, and they have
been widely used combined with MeOH as extraction solvent [29,30]. By quantitatively
precipitating proteins, Captiva ND-Lipid filters could be avoided. However, considering
the risk that those acids suppose, extremely precautious handling is needed. Therefore, a
weaker acid like HOAc was also tested as a safer alternative.
In this sense, four experiments were performed employing different extractants:
(i) AcN, (ii) MeOH:HOAc (95:5, v/v), (iii) MeOH:TFA (80:20, v/v) and (iv) MeOH:TCA
(80:20, v/v). In all the cases, centrifugation and cold protein precipitation was performed,
while in the assays done with pure AcN a further clean-up using the Captiva ND-Lipids
filters was performed. To estimate the recovery of the procedures, external calibration was
used to calculate the concentration of spiked milk samples (n = 3) at 50 ng/g concentration
in milk. As for precision, it was estimated in terms of relative standard deviation (RSD)
of the 3 replicates. To establish a criterion for discarding analytes, only analytes with
recoveries in the 10–180% range and RSDs < 30% were considered as “detected analytes”
in all optimization experiments.
TFA and TCA in MeOH proved to be effective to promote severe protein precipitation
and the use of Captiva ND-Filters could be avoided. However, HOAc was not strong
enough to quantitatively precipitate proteins, being the procedure inviable (data not
shown). The introduction of TFA and TCA, however, led to the loss of several analytes
diverse in terms of polarity and acidity/basicity due to the extraordinarily strong acidic
media set. In fact, recoveries around 40–60% and higher RSD values (mean 12%) were
obtained for the detected analytes (less than 80% in both approaches). Using AcN as
extractant and Captiva ND-Lipids for clean-up instead, recoveries between 40% and 108%
(mean 76%) and RSDs in the 2–16% (mean 9%) range were obtained for the detected
analytes (82%), respectively.
Bearing in mind that the proposed methodology should be useful for suspect screening
analysis, the use of those strong acids was discarded since they allowed the extraction of a
lower number of targets with lower recovery values. Taking those reasons into a consider-
ation, AcN was chosen as extraction solvent and Captiva ND-Lipids for protein removal.
However, in all the experiments fluoroquinolones (FQs) were not properly detected, proba-
bly due to their chelation to free calcium ions (Ca2+) in the liquid milk [29,31], so different
strategies were tested to favour their detection.
3.2. Fluoroquinolones, EDTA and Oasis HLB Optimization
According to literature, EDTA is useful for breaking down the chelation between Ca2+
and FQs since it creates very stable chelates with polyvalent cations [29,30]. Therefore, the
extracts obtained from Captiva ND-Lipid filters were dried and reconstituted in EDTA.
In that context, reverse phase SPE was needed to perform solvent change from water to
MeOH and preconcentrate analytes. According to the literature, Oasis HLB was chosen to
fulfil that aim. Moreover, the introduction of Oasis HLB combined with Captiva ND-Lipids
would provide even cleaner extracts, since Oasis HLB has been widely used to clean-milk
extracts [29,30,37].
In a first approach, Oasis HLB was used at different pH values (4.0, 6.0, and 9.0) in
order to check which pH allowed the preconcentration and subsequent detection of the
maximum of compounds with the highest recovery. The recoveries for each condition are
shown in Figure 1 as box plots.
As can be observed, the recoveries for the procedures using Oasis HLB at the tested pH
values were acceptable, being most of them between 40% and 65%. The highest percentage
of detected analytes was at pH 4.0 (76%) and pH 6.0 (75%) compared to pH 9.0 (64%).
However, overall higher recoveries were obtained at pH 4.0 than at pH 6.0. Moreover,
FQs were correctly detected at all of the experiments, showing that they were detached
from Ca2+ ions and well retained at the Oasis HLB independently of the pH. Taking all the
observations into account, pH 4.0 was chosen as the optimal pH for Oasis HLB use.




Figure 1. Boxplots of the recoveries (%) for Oasis HLB clean-up at pH 4.0, 6.0 and 9.0, showing 
minimum and maximum values (whiskers), percentiles (Q1 and Q3), average (x), median (line) and 
outliers (points). 
As can be observed, the recoveries for the procedures using Oasis HLB at the tested 
pH values were acceptable, being most of them between 40% and 65%. The highest per-
centage of detected analytes was at pH 4.0 (76%) and pH 6.0 (75%) compared to pH 9.0 
(64%). However, overall higher recoveries were obtained at pH 4.0 than at pH 6.0. More-
over, FQs were correctly detected at all of the experiments, showing that they were de-
tached from Ca2+ ions and well retained at the Oasis HLB independently of the pH. Taking 
all the observations into account, pH 4.0 was chosen as the optimal pH for Oasis HLB use. 
3.3. Addition of Salts and EDTA to the Extraction Solvent 
Going further into the optimization, the influence of additives such as salts and 
EDTA in the extraction solvent was studied. According to the applications found in the 
literature, MgSO4, Na2SO4 and NaCl are the most used salts in the extraction of xenobiotics 
in milk [17,25,34]. Therefore, different combinations of extractants with salts were tested: 
(i) AcN with NaCl, (ii) AcN with Na2SO4 and NaCl, and (iii) AcN with MgSO4 and NaCl. 
However, since magnesium could also interfere with FQs in the same way as the calcium 
in the milk, separate extractions were set up by (iv) extracting first with AcN and subse-
quently with AcN, MgSO4, and NaCl. This way, the extraction of the maximum number 
of compounds was ensured. In all the cases, centrifugation, cold protein precipitation and 
Captiva ND-Lipids filtering steps were included. Moreover, all the approaches were also 
tested with Oasis HLB at pH 4.0 after reconstructing the dried extract from Captiva ND-
Lipids filters in EDTA (30 mM, pH 4.0). 
Furthermore, an additional experiment was carried out by adding EDTA to AcN in 
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Figure 1. Boxplots of the recoveries (%) for Oasis HLB clean-up at pH 4.0, 6.0 and 9.0, showing
minimum and maximum values (whiskers), percentiles (Q1 and Q3), average (x), median (line) and
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3.3. Addition of Salts and EDTA to the Extraction Solvent
Going further into the optimization, the influence of additives such as salts and
EDTA in the extraction solvent was studied. According to the applications found in
the literature, MgSO4, Na2SO4 and NaCl are the most used salts in the extraction of
xenobiotics in milk [17,25,34]. Therefore, different combinations of extractants with salts
were tested: (i) AcN with NaCl, (ii) AcN with Na2SO4 and NaCl, and (iii) AcN with
MgSO4 and NaCl. However, since magnesium could also interfere with FQs in the same
way as the calcium in the milk, separate extractions were set up by (iv) extracting first
with AcN and subsequently with AcN, MgSO4, and NaCl. This way, the extraction of
the maximum number of compounds was ensured. In all the cases, centrifugation, cold
protein precipitatio and Ca tiva ND-Lipids filtering steps were included. Moreover, all
the approaches were also t sted with Oasis HLB at pH 4.0 after reconstructing the dri d
extract from Captiva ND-Lipids filters in EDTA (30 mM, pH 4.0).
Furthermore, an additional xperi ent was carried out by adding EDTA to AcN in
the extraction solvent to check whether it would be useful for breaking down the chel tion
between the Ca2+ ions and the FQs prior extraction. The extractant used was (v) AcN:Milli-
Q water 0.1% EDTA (95:5, v/v) and therefore the use of Oasis HLB was not necessary in
that case. Table 1 summarizes the recoveries of the whole procedure for each experiment
with the % of detected compounds.
Table 1. Results of the experiments to optimize the addition of salts.
Experiment
Without Oasis HLB With Oasis HLB
Detected (%) Recoveries (%) * Detected (%) Recoveries (%) *
(i) AcN + NaCl 88 63–92 (80) 88 9–93 (46)
(ii) AcN + Na2SO4 + NaCl 92 68–110 (90) 82 9–122 (44)
(iii) AcN + MgSO4 + NaCl 84 50–110 (78) 78 30–111 (69)
(iv) 1. AcN,2. AcN + MgSO4 + NaCl
89 58–101 (81) 79 26–118 (50)
(v) AcN:Milli-Q water 0.1%EDTA (95:5, v/v) 81 7–85 (47)
Not
performed Not performed
* Recoveries are represented as the range and the mean recovery (in brackets) of all detected compounds.
The addition of EDTA in the extraction solvent allowed the detection of FQs by break-
ing down the chelation between the compounds and Ca2+ in the solution. Nevertheless,
the water content in the extraction solution increased evaporation time of the extracts. Not
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only that, but the recoveries were also, in general, worse than in the rest of experiments
for the rest of compounds. Based on those observations and with the main aim of de-
tecting as many compounds as possible, the addition of EDTA to the extraction solvent
was discarded.
However, the addition of salts improved the recoveries due to salting-out effect.
Regarding method throughput, the addition of anhydrous Na2SO4 or MgSO4 turned out
as compulsory to remove moisture and to make the procedures much less time-consuming.
Comparing the results obtained with both salts, Na2SO4 provided slightly better results
since it allowed the detection of more compounds than MgSO4, including FQs. Moreover,
in the experiments where consecutive extractions were performed, better results were
obtained comparing to a single extraction with MgSO4.
As it can be concluded from the experiments using Oasis HLB, lower recoveries were
obtained due to the extended procedure, leading to the loss of more analytes. To accurately
assess the effect of Oasis HLB in the additional clean-up, matrix-effect at detection was
studied. Matrix-effect at the detection was calculated by spiking at 300 ng/g just after
the whole treatment of non-spiked milk and calculating the concentration using external
calibration. The results are gathered at Table 2 and values close to 100% represent lack
of matrix-effect. However, the protocols using EDTA in the extraction solvent and a
single extraction with MgSO4 were discarded since the other approaches provided more
promising results.
Table 2. Matrix-effect (%) at detection.
Experiment
Without Oasis HLB With Oasis HLB
Recoveries (%) * Recoveries (%) *
(i) AcN + NaCl 85–115 (109) 72–108 (97)
(ii) AcN + Na2SO4 + NaCl 92–119 (109) 81–112 (101)
(iv) 1. AcN,2. AcN + MgSO4 + NaCl
95–128 (114) 83–113 (102)
* Recoveries are represented as the range and the mean recovery (in brackets) of all detected compounds.
The outcomes of the experiments showed that similar matrix-effect was observed at
the detection with and without Oasis HLB. However, this additional clean-up lowered
absolute recoveries of the whole treatment and also led to a reduced number of detected
compounds, whereas the addition of Na2SO4, promoted a higher number of compounds
detected with reasonably good recoveries. All in all, it was the best approach considering
lab viability, number of detected analytes and their respective recoveries with almost no
matrix-effect. Based on all those observations, method validation was performed under
those optimal conditions that consisted of performing the extraction with AcN, NaCl and
Na2SO4 by vortex, and protein removal by centrifugation, precipitation at low temperature,
and filtration through Captiva ND-Lipids filters.
3.4. Validation
The optimized analytical procedure to determine polar organic xenobiotics in milk was
validated at two concentration levels, by spiking whole bovine milk at 10 ng/g and 40 ng/g
for 245 compounds (214 used in the optimization plus 31 new compounds introduced for
validation). All the results were corrected using the signals obtained from the procedural
blanks, which included several phthalates leached from the plastic material used through-
out the analytical process. All the results are individually collected at Supplementary
Table S2. The figures of merit of the optimized method are described hereinafter.
3.4.1. Instrumental and Procedural Limits of Quantification (LOQs)
Low-concentration points from the external (2, 5, 10, 25, and 50 ng/g in the extract)
and matrix-matched (1, 2, 5, and 10 ng/g in the sample) calibration curves were injected
in triplicate for calculating instrumental (LOQinst) and procedural (LOQproc) LOQs, re-
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spectively (see Section 2.7). In order to set the limits, precision and systematic error were
considered. As for the precision, it was determined as the RSD (%) of the three replicates.
With regards to the systematic error, it was calculated as the difference of the calculated
and the real concentration (%) of the calibration points. LOQs were, therefore, set as the
lowest concentration value fitting into a lineal calibration curve with RSD and systematic
error values lower than 30% (see Supplementary Table S2 for LOQs).
For most analytes (213 out of 245, 87%), excellent LOQinst (below 20 ng/g) were
obtained. The worst values, ranging between 100 and 200 ng/g, were obtained for BPA, flu-
tamide, meclocycline and metribuzin. Considering the LOQproc, almost all analytes (90%,
221/245) provided results lower than 10 ng/g. The analytes with the highest LOQproc val-
ues (below 55 ng/g) were captopril, methotrexate, ciprofloxacin, di-octyl phthalate (DOP),
gabapentin, bis(2-ethylhexyl)phthalate (DEHP), meclocycline and hydroxychloroquine.
According to literature, LOQproc lower than 30 ng/g have been obtained in the analysis
of xenobiotics in milk samples [17,24,49]. However, it is worth mentioning that, in most
cases, softer criteria were chosen to set LOQ values, with the only requirement being the
signal-to-noise ratio (S/N) to be higher than 10. Moreover, in those works less analytes
were studied, most of them focusing only on specific xenobiotics families, such as drugs or
endocrine disruptors [17,24,49].
3.4.2. Linearity-Ranges and Determination-Coefficients (r2)
Linearity ranges for external and matrix-matched calibrates were studied by the deter-
mination coefficients (r2) that are collected at Supplementary Table S2 for each compound.
The external calibrations, built between LOQinst and 300 ng/g, provided high r2 values
since only 7 compounds (3%) had lower values than 0.9500. These compounds were
DEHP, ciprofloxacin, DOP, enoxacin, meclocycline, norfloxacin and nonylphenol, for which
semi-quantitative analysis was considered.
In the case of the r2 values of the matrix-matched calibrations built between LOQproc
and 60 ng/g in the sample, slightly worse values were obtained as expected, since each
concentration point of the calibrate underwent separately the analytical procedure. In this
case, 94% of the analytes provided r2 values higher than 0.9500 and for the rest (6%), semi-
quantitative analysis was considered. These compounds were nonylphenol, DOP, dibutyl
phthalate (DBP), ofloxacin, enoxacin, metribuzin, gabapentin, parathion, enrofloxacin,
ranitidine, caprolactam, metformin, imatinib, bis(2-ethylhexyl)adipate (BEHA), and DEHP.
3.4.3. Absolute and Apparent Recoveries
Absolute recoveries (%) were determined as the ratio of the concentrations calculated
from the external calibration and the spiked concentration. As for the apparent recoveries,
those were calculated using two different approaches: (i) correction using isotopically
labelled surrogates and (ii) matrix-matched calibration. The correction using surrogates
was applied to each absolute recovery value with every surrogate, and the corrected
apparent recovery closest to 100% with the lowest RSD value was chosen for each target
analytes when possible. Which surrogate was chosen for each analyte whenever possible is
also collected in Supplementary Table S2. In the case of the matrix-matched calibration, the
apparent recoveries were determined by the ratio of the concentrations calculated from the
curve and the spiked concentration.
Absolute and apparent recoveries obtained at low (10 ng/g) and high (40 ng/g) con-
centrations are shown as box-plots in Figure 2a,b, respectively, while the results for each
analyte are gathered in Supplementary Table S2. Recoveries between 70% and 130% were
considered as satisfactory while semi-quantitative analysis was considered for compounds
out of this recovery range.
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Figure 2. Absolute and apparent (surrogate correction and matrix-matched) recoveries (%) spiking
milk samples at: (a) 10 n /g and (b) 40 ng/g.
At low concentration (Figure 2a), absolute recoveries were properly determined for
88 analytes (36%), since most of them showed values below 70% (mean value 73%). As
for the apparent recoveries, considerably better results were obtained. With surrogate
correction, absolute recoveries for 127 analytes (52%) were corrected with the mean value
of the apparent recoveries being 86% while with matrix-matched calibration, apparent
recoveries for 210 (86%) were properly determined (mean value 96%).
At high concentration (Figure 2b), higher absolute recoveries were obtained since
119 analytes were within the satisfactory range (mean 83%). With surrogate correction,
the apparent recoveries for 140 analytes were acceptable (mean value 87%) and using
matrix-matched good apparent recoveries between 70% and 130% (mean 110%), were
obtained for 220 analytes.
Comparing the apparent recoveries obtained from both strategies, matrix-matched
calibration rendered better results than surrogate correction. In order to improve the results
obtained using surrogate correction, a larger number of labelled standards is necessary.
In this sense, even though matrix-matched calibration requires more lab work, it is more
profitable since expensive surrogates can be avoided. On the downside, the sample in which
matrix-matched calibration curves are built can differ from the samples analysed and this
drawback can be avoided when proper surrogates are available for each target compound.
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3.4.4. Instrumental and Procedural Repeatability
Instrumental and procedural repeatability were calculated in terms of RSD of the
three injections of the 50 ng/g point from the external calibration and the three replicates
analysed at each spiked concentration-level, respectively. For the procedural repeatability,
RSD values at low and high concentrations were determined in the case of both absolute
and apparent recoveries (four repeatability values for each compound). Since apparent
recoveries were calculated by surrogate correction or matrix-matched, the highest value
(worst scenario) was set for each analyte in each case. The results are gathered at Table 3
(see the specific values for each analyte at Supplementary Table S2).
Table 3. Instrumental and procedural repeatability values in terms of RSD (%) for absolute (abs.) and
apparent (app.) recoveries at low and high concentrations.
Repeatability Concentration
Number of Analytes
<10% 10–20% 20–50% >50%




Abs. rec. 183 37 16 9
App. rec. 191 34 13 7
40 ng/g
(milk)
Abs. rec. 197 26 15 7
App. rec. 195 28 15 7
As can be seen in Table 3 above, most analytes provided instrumental RSD values
lower than 10%, showing the repetitiveness of the UHPLC-qOrbitrap measurements.
Considering procedural values, higher RSDs were obtained as expected. Nevertheless,
the repeatability was still acceptable with most analytes rendering values below 20%.
Moreover, slightly better results were obtained at high concentrations as foreseen.
In a similar multi-target work where 200 xenobiotics were analysed with UHPLC-
qOrbitrap, also RSD values lower than 20% were obtained for instrumental repeatabil-
ity [45]. For procedural repeatability, also RSD values below 20% have been obtained while
determining xenobiotics in milk samples, even though no other work has analysed more
than 200 compounds [17,23,25,36].
3.4.5. Instrumental and Procedural Limits of Identification (LOIs)
For the calculation of LOIs, the external and matrix-matched calibration points (in-
strumental, LOIinst, and procedural, LOIproc, values, respectively) were considered under a
suspect screening approach using Compound Discoverer 3.1 (see Section 3.5). The lowest
concentration values where the analytes could be identified were set as the LOIs (see
Supplementary Table S2).
Overall, the LOIs for most compounds were below 10 ng/g. Regarding instrumental
LOIs, analytes with higher values than 50 ng/g were naproxen, indomethacin, meclocy-
cline, ethion, 2,6-di-tert-butyl-4-(dimethylaminomethyl)phenol, benzothiazole, fenthion,
ciprofloxacin, enoxacin, pendimethalin, oryzalin, danofloxacin, enrofloxacin, glycitin,
genistin, celecoxib, and hydrochlorothiazide. As for the procedural LOIs, the following an-
alytes provided values higher than 20 ng/g: bis(methylglycol)phthalate, acyclovir, sotalol,
captopril, naproxen, pyrantel, DOP, ethion, indomethacin, ranitidine, meclocycline, mon-
telukast, enoxacin, erythromycin, oryzalin, 2,6-di-tert-butyl-4-(dimethylaminomethyl)phenol,
hydroxychloroquine, and glycitin.
Since very few works performing suspect screening or non-target analysis of water-
soluble organic xenobiotics in milk are available, identification limits are poorly investi-
gated. Some works use limits of decision to set minimum concentration values at which
xenobiotics need to be present in to identify them [31]. However, this parameter is calcu-
lated following the EU 2002/657/EC regulation [50] that does not require suspect screening
approaches to set the values. Some works have determined LOIs for these kind of xeno-
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biotics but in other complex matrices such as swine manure and fish muscle, with the
instrumental values being lower than 30 ng/g [45,51].
3.5. Target Analysis of Commercial and Breast Milk Samples
Target analysis was performed in three commercial (whole bovine milk, raw bovine
milk and freeze-dried milk powder) and four breast milk (labelled A, B, C and D) samples,
following the details mentioned in Section 2.6. The concentration values were corrected by
surrogates or matrix-matched whenever possible, taking into account the results from the
validation, and expressed with 95% confidence level (2s, s being the standard deviation of
the 3 procedural replicates). Only results that provided lower RSD values than 35% are
shown in the Table 4 (commercial milk) and Table 5 (breast milk).
Although several compounds were detected in treated whole and untreated bovine
milk samples, most of them were below LOQs, except for acetaminophen (anti-inflammatory
drug) and DOP (plasticizer) in the untreated milk, which have been previously deter-
mined in bovine milk [52,53]. In the freeze-dried milk powder samples, instead, sev-
eral diverse compounds were quantified such as, benzothiazole (food additive), caf-
feine (stimulant), genistein, genistin and glycitin (phytoestrogens) and 2-ethylhexyl-4-
dimethylaminobenzoate ((EHDAB, UV filter).
Table 4. Target analysis results: concentration of xenobiotics (95%, 2 s) in commercial milk samples.
Compound Whole Bovine Milk (ng/g) Raw Bovine Milk (ng/g) Milk Powder (ng/g)
Acetaminophen m n.d 3.2 ± 0.4 n.d
Benzothiazole a n.d n.d 11 ± 6
Caffeine c n.d n.d 2.0 ± 0.1
EHDAB m n.d n.d 0.70 ± 0.04
Genistein n.d n.d 20.1 ± 0.3
Genistin n.d n.d 29 ± 1
Glycitin n.d n.d 4.7 ± 0.6
2-Hydroxybenzothiazole <LOQ n.d <LOQ
Azoxystrobin n.d <LOQ n.d
Benzethonium n.d <LOQ n.d
Bicalutamide <LOQ <LOQ <LOQ
BEHA n.d <LOQ n.d
BEHP n.d <LOQ n.d
Butylparaben <LOQ <LOQ <LOQ
Carbendazim <LOQ n.d n.d
Cortisone <LOQ <LOQ <LOQ
Cotinine <LOQ n.d <LOQ
Crotamiton n.d <LOQ n.d
Diethyl Toluamide <LOQ <LOQ <LOQ
DOP m n.d <LOQ n.d
Enrofloxacin <LOQ n.d n.d
Fenpropimorph <LOQ <LOQ <LOQ
Finasteride n.d n.d <LOQ
Ifosfamide n.d <LOQ <LOQ
Methylparaben <LOQ n.d n.d
Pirimicarb <LOQ <LOQ <LOQ
Pirimiphos-methyl n.d n.d <LOQ
Primidone <LOQ <LOQ <LOQ
Progesterone <LOQ n.d n.d
Propiconazole n.d <LOQ n.d
Pyrazophos <LOQ n.d n.d
Sulfamethazine <LOQ n.d n.d
Sulfamethoxazole <LOQ n.d n.d
Terbutryn <LOQ <LOQ <LOQ
Superscript: (a) [2H5]-atrazine, (c) [13C3]-caffeine, (m) matrix-matched. Data abbreviations: below limit of quantification (<LOQ),
non-detected (n.d). Compounds abbreviations: 2-ethylhexyl-4-dimethylaminobenzoate (EHDAB), bis(2-ethylhexyl)adipate (BEHA),
bis(2-ethylhexyl)phthalate (BEHP), di-n-octyl phthalate (DOP).
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Table 5. Target analysis results: average concentration of xenobiotics (95%, 2 s) in breast milk samples.
Compound A (ng/g) B (ng/g) C (ng/g) D (ng/g)
Benzophenone n.d n.d 4 ± 1 n.d
Benzothiazole 45 ± 4 n.d n.d n.d
BEHP m 45 ± 30 n.d 48 ± 29 n.d
Caffeine c 988 ± 127 35 ± 2 33 ± 3 1011 ± 210
Caprolactam 27 ± 2 n.d n.d n.d
DOP m 39 ± 27 n.d 41 ± 26 n.d
EHDAB m n.d n.d n.d 0.58 ± 0.01
MBHB c <LOQ n.d 4 ± 2 n.d
Orlistat n.d n.d 2.3 ± 0.4 n.d
Triethyl phosphate n.d n.d 20 ± 8 n.d
2,4-Dinitrophenol <LOQ n.d n.d n.d
Azoxystrobin n.d <LOQ n.d n.d
Benzethonium n.d <LOQ n.d n.d
Bicalutamide n.d <LOQ <LOQ <LOQ
BEHA n.d n.d <LOQ n.d
BPA <LOQ n.d n.d n.d
Butylparaben <LOQ <LOQ <LOQ <LOQ
Cotinine <LOQ <LOQ <LOQ n.d
Crotamiton <LOQ n.d <LOQ <LOQ
DBP n.d n.d <LOQ n.d
Diethyl Toluamide <LOQ n.d <LOQ <LOQ
Exemestane n.d n.d <LOQ n.d
Fluvoxamine n.d n.d <LOQ n.d
MBP <LOQ n.d n.d n.d
Medroxyprogesterone <LOQ <LOQ <LOQ n.d
Methylparaben <LOQ n.d n.d n.d
Norfloxacin n.d n.d <LOQ n.d
Pindolol n.d <LOQ n.d <LOQ
Pirimicarb <LOQ <LOQ <LOQ <LOQ
Propiconazole <LOQ <LOQ <LOQ <LOQ
Sotalol <LOQ n.d n.d <LOQ
Sulfamethoxazole <LOQ n.d n.d n.d
Tamoxifen <LOQ n.d <LOQ n.d
Trimethoprim n.d n.d <LOQ n.d
Triphenylphosphate <LOQ n.d n.d n.d
Superscript: (c) [13C3]-caffeine, (m) matrix-matched. Data abbreviations: below limit of quantification (<LOQ), non-detected (n.d). Com-
pounds abbreviations: bis(2-ethylhexyl)phthalate (BEHP), di-n-octyl phthalate (DOP), 2-ethylhexyl-4-dimethylaminobenzoate (EHDAB),
methyl 3,5-di-tert-butyl-4-hydroxybenzoate (MBHB), bis(2-ethylhexyl)adipate (BEHA), bisphenol A (BPA), dibutyl phthalate (DBP),
methylbenzophenone (MBP).
As far as breast milk samples are concerned, caffeine was quantified at high concen-
tration (33–1011 ng/g) in all of the samples, which was not surprising since it is common
in several foods and drinks that are regularly taken by humans through the diet, and it has
been detected in breast milk in other works as well [25,36]. Moreover, compounds such
as DEHP and DOP (plasticizers) were quantified in half of the samples analysed, while
benzophenone and EHDAB (UV filters), orlistat (pharmaceutical), caprolactam and tri-
ethyl phosphate (industrial chemicals) and benzothiazole (food additive) were punctually
detected. Several other xenobiotics were detected below LOQs.
3.6. Suspect Analysis of Commercial and Breast Milk Samples
Suspect screening was performed under the conditions described in Section 2.6, which
allowed the identification of 50 xenobiotics of diverse origin (natural or artificial) at different
identification levels [54] in the milk samples. The distribution of the confidence levels for
the xenobiotics’ identification is represented in Figure 3.
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Figure 3. Distribution of the identification confidence levels of the xenobiotics by suspect screening.
Among the identified compounds, 13 (26%) were identified at level 1 by confirmation
via pure standard, precisely, the compounds quantified via target analysis. A wide variety
of xen biotics (24%) were confirmed at level 2a since library d a from mzCloud was used
for MS2 confirmation. Some ubiquitou xenobiotics in commercial milk samples were
4-indolecarbaldehyde (plant etabolite), bis(2-ethylhexyl) amine (surfactant), isoquinoline
(alkaloid) or s ccharin (artificial sweetener), while in breast milk samples was frequent to
find xenobiotics such as 2-(8-hydroxy-4a,8-dimet yldec hydro-2-naphthalenyl)acrylic acid
(sesquiterpene), 2,5-di-tert-butylhydroquinone (industrial chemical), 4-indolecarbaldehyde
(algal metabolite), avobenzone (UV filter), piperine (alkaloi ), saccharin (artificial sweet-
ener), or shogaol (plant component).
Several other xenobiotics like indoles or quinolones were identified in commercial
and breast milks but it was not possible to differentiate between isomers (level 3, 10%).
Indoles are industrially used as synthetic favouring compounds for perfume fixative roles,
or they can be directly present in tobacco smoke [55]. As for the quinolones, they are broad-
spectrum antibiotics which have been previously detected in breast milk samples [56]. For
other detected xenobiotics, it was not possible to annotate their MS2 (level 4, 16%).
As it has been observed, some xenobiotics were derived from plants, and are likely
less harmful than the artificial ones. All the xenobiotics identified at each level are collected
in Table 6 indicating the ones with natural origin, while the extracted ion chromatograms
(EICs) of xenobiotics identified at level 1 and 2a in each commercial and breast milk sample
are gathered in Supplementary Figures S1–S9.
Table 6. Suspect screening of commercial and breast milk: xenobiotics identified at level 1, 2a, 3 and 4.
Comme cial Milk Breast Milk
Annotated Compound MolecularFormula
Exact
Mass tR (min) 1 2 3 A B C D
[M+H]+
Level 1
Acetaminophen C8H9NO2 151.06333 1.77 X ! X X ! X X
BEHP C24H38O4 390.27701 15.90 X X X ! X ! X
Benzophenone C13H10O 182.07316 11.75 X X X X X ! X
Benzothiazole C7H5NS 135.01427 6.50 X X ! ! X X X
Caffeine C8H10N4O2 194.08038 2.50 X X ! ! ! ! !
Caprolactam C6H11NO 113.08406 2.35 X X X ! X X X
DOP C24H38O4 390.27701 15.90 X <LOI X <LOI X <LOI X
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Table 6. Cont.
Commercial Milk Breast Milk
Annotated Compound MolecularFormula
Exact
Mass tR (min) 1 2 3 A B C D
EHDAB C17H27NO2 277.20418 14.50 X X <LOI X X X <LOI
Genistein * C15H10O5 270.05282 7.55 X X ! X X X X
Genistin * C21H20O10 432.10565 4.30 X X ! X X X X
Glycitin * C22H22O10 446.12130 3.43 X X <LOI X X X X
MBHB C16H24O3 264.17256 13.60 X X X <LOI X <LOI X
Triethyl phosphate C6H15O4P 182.0708 5.70 X X X X X ! X
Level 2a
1,2,3,9-tetrahydro-4H-
carbazol-4-one oxime C12H12N2O 200.09496 4.99 ! X X X X X X
3-Acetyl-2,5-









C22H36O3 348.26645 13.70 X ! X ! ! ! X
4-Indolecarbaldehyde * C9H7NO 145.05276 3.05 ! ! ! X ! ! X
4-Methoxycinnamic acid * C10H10O3 178.06299 7.04 X X X ! X X X
5-Hydroxymethyl-2-




C17H13NO2 263.09463 12.09 ! ! X X X X X
Amfepramone C13H19NO 205.14666 5.66 X X X ! X X X
Avobenzone C20H22O3 310.15689 14.40 X X X X ! ! X
Bis(2-ethylhexyl) amine C16H35N 241.27695 11.34 ! X ! X X X X
Carvone C10H14O 150.10447 11.72 X X X X X ! X
Citroflex A-4 C20H34O8 402.22537 14.00 X ! X X X X X
Didecyldimethylammonium C22H47N 325.37085 12.60 X X X ! X X X
Isoquinoline * C9H7N 129.05785 3.80 ! ! ! X X X X
Nootkatone C15H22O 218.16707 12.95 X X X X X ! X
OPEO C16H26O2 250.19328 13.07 X X X X ! ! !
Piperine * C17H19NO3 285.13649 11.81 X X ! X X ! !
Shogaol * C17H24O3 276.17254 10.70 X ! X ! ! ! X
Tetramethylene sulfoxide C4H8OS 104.02959 1.46 X X X ! X X X
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Table 6. Cont.
Commercial Milk Breast Milk
Annotated Compound MolecularFormula
Exact





C8H7NO 133.05276 1.54 ! ! ! X X X X
2-Hydroxyquinoline/
8-Hydroxyquinoline * C9H7NO 145.05276 3.95 ! X ! X X X X
1,5-Isoquinolinediol/
2,4-Quinolinediol C9H7NO2 161.04768 4.17 ! ! ! X X X X
1,5-Isoquinolinediol/
2,4-Quinolinediol C9H7NO2 161.04768 4.48 ! X X X X X X
Paraxanthine/Theophylline/






C8H7NO 133.05276 4.68 ! X ! ! ! ! !
Pulegone/D,L-


























C20H26O3 314.18819 12.45 X X ! X X ! X
N-Benzylformamide/
Phenacylamine C8H9NO 135.06841 3.13 ! ! ! X X ! !
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Table 6. Cont.
Commercial Milk Breast Milk
Annotated Compound MolecularFormula
Exact






C15H24O3 252.17254 10.82 X X X ! X ! X
2,5-di-tert-
Butylhydroquinone C14H22O2 222.16198 12.49 X X X ! ! ! !
Myristyl sulfate C14H30O4S 294.18648 12.22 X X X ! X X !
Saccharin C7H5NO3S 182.99901 1.38 ! ! ! ! ! ! X
Level 4
Chrysin/Daidzein/
Abietic acid C15H10O4 254.05791 6.09 X X ! X X X X
* Natural origin.
4. Conclusions
In this work, a multi-target method able to determine more than 200 xenobiotics in
commercial and breast milk samples was developed, which was later extended to perform
suspect screening using a database that contains almost 18,000 xenobiotic compounds.
Although in most works dealing with contaminants in milk samples, mainly non-polar
compounds are assessed, in this work, the monitoring of compounds with a wide range
of polarities was carried out. Bearing in mind that aim, the optimal conditions for the
analytical procedure were set to detect as many compounds as possible in the milk samples
with an efficient lipid and protein removal.
In the optimized procedure, the importance of salts, such as anhydrous Na2SO4 and
NaCl, was highlighted, which not only made the procedure straightforward due to moisture
removal, but also enhanced the recoveries because of the salting-out effect. Moreover,
Captiva ND-Lipids successfully removed co-extracted lipids and proteins ensuring high
recoveries for the rest of analytes, without the need of a further clean-up using SPE
HLB cartridges.
The optimal procedure to determine xenobiotics in milk was validated at two con-
centration levels by spiking the milk samples with the target 245 analytes at 10 ng/g and
40 ng/g. Most analytes (220) were validated at high concentration showing apparent
recoveries between 70% and 130% that were determined by surrogate correction and/or
matrix-matched calibration. As for the rest of figures of merit, satisfactory results were
obtained considering the complexity of the matrix, the wide variety of analytes and the
small sample amount (1 mL) used. However, the use of isotopically labelled compounds
should be further studied in the future since only five surrogates were used in this work.
The optimized multi-target procedure was successfully applied to quantify xenobiotics
in 3 different commercial milk samples: treated and untreated raw bovine milk and freeze-
dried milk powder. The liquid milk samples turned out to be almost free of the targeted
xenobiotics since only acetaminophen (anti-inflammatory) and DOP (plasticizer) were
quantified in the raw milk samples. However, several compounds were quantified in the
milk powder, such as benzothiazole (food additive), caffeine (stimulant), genistein, genistin
and glycitin (phytoestrogens), and EHDAB (UV filter).
Regarding breast milk samples, even though caffeine (stimulant) was quantified at
the highest concentration in all of the samples, other xenobiotics such as DEHP and DOP
(plasticizers), benzophenone and EHDAB (UV filters) were also found. Apart from those
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xenobiotics, a wide variety of other xenobiotics that were not included in the target list
were identified by suspect screening at different confidence-levels including personal and
pharmaceutical products, food additives, and disinfectants.
Although the presence of non-polar compounds is often expected in milk samples,
the screening of compounds with a broad range of polarities is advisable in biomonitoring
programs in order to have more information about the exposome. The suitability of the
multi-target and suspect screening method for the analysis of milk samples opens the
opportunity to extend the optimized method to other biological fluids such as blood or
urine, to get a more holistic understanding of the exposome and find out the relationship
between exposure to xenobiotics and adverse health effects.
Supplementary Materials: The following are available online at https://www.mdpi.com/2297-8
739/8/2/14/s1, Figure S1: Extracted ion chromatograms (EICs) of the identified compounds at
confidence level 1 and 2a in commercial treated milk by suspect screening in positive ionization
modes, Figure S2: Extracted ion chromatograms (EICs) of the identified compounds at confidence
level 1 and 2a in commercial raw milk by suspect screening in positive ionization modes, Figure S3:
Extracted ion chromatograms (EICs) of the identified compounds at confidence level 1 and 2a in
commercial powder milk by suspect screening in positive ionization modes, Figure S4: Extracted
ion chromatograms (EICs) of the identified compounds at confidence level 1 in breast milk A by
suspect screening in positive ionization modes, Figure S5: Extracted ion chromatograms (EICs) of
the identified compounds at confidence level 2a in breast milk A by suspect screening in positive
ionization modes, Figure S6: Extracted ion chromatograms (EICs) of the identified compounds at
confidence level 1 and 2a in breast milk B by suspect screening in positive ionization modes, Figure S7:
Extracted ion chromatograms (EICs) of the identified compounds at confidence level 1 in breast milk
C by suspect screening in positive ionization modes, Figure S8: Extracted ion chromatograms (EICs)
of the identified compounds at confidence level 2a in breast milk C by suspect screening in positive
ionization modes, Figure S9: Extracted ion chromatograms (EICs) of the identified compounds at
confidence level 1 and 2a in breast milk D by suspect screening in positive ionization modes, Table S1:
Information and physicochemical properties of the 245 target analytes, Table S2: Validation results
for the target 245 analytes: instrumental (UHPLC-qOrbitrap) and procedural (Vortex—Captiva
ND-Lipids—UHPLC-qOrbitrap) figures of merit.
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